It was observed that systemic administration of PEGylated human IL-10 (pegilodecakin) promotes infiltration, activation and intratumor expansion of tumor-specific CD8+ T cells and restores their cytotoxic activity, resulting in enhanced granzyme B and IFN-γ production in CD8+ cells, enhanced intratumor antigen presentation and induction of anti- tumor immune response with evidence of clinical benefits in different advanced solid tumors, such as renal cell carcinoma and uveal melanoma (112, 191, 197, 198). The gene discussed is CD8A; the disease is renal cell carcinoma.